Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $58.40.

A number of analysts have commented on ELVN shares. The Goldman Sachs Group lifted their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Mizuho lifted their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. HC Wainwright lifted their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Finally, Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th.

Enliven Therapeutics Price Performance

ELVN stock opened at $39.57 on Monday. The firm has a market cap of $2.41 billion, a PE ratio of -23.69 and a beta of 0.29. The business has a 50 day moving average of $40.98 and a 200 day moving average of $29.67. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. On average, research analysts expect that Enliven Therapeutics will post -1.59 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 10,000 shares of Enliven Therapeutics stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. This trade represents a 16.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. KBC Group NV purchased a new position in shares of Enliven Therapeutics in the 1st quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the last quarter. Quantbot Technologies LP boosted its stake in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the last quarter. Finally, AlphaQuest LLC purchased a new position in shares of Enliven Therapeutics in the 3rd quarter worth $96,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.